Skip to main content
. 2018 Mar 28;38(13):3346–3357. doi: 10.1523/JNEUROSCI.3245-17.2018

Figure 6.

Figure 6.

Reduced seizure susceptibility and extended lifetime in LGI1−/− (KO) mice after celecoxib injection. A, Cortical EEG recordings from WT and KO mice. The epileptiform discharge was remarkably inhibited in celecoxib-treated KO mice at P16 but recurred after P20. B, Kaplan–Meier survival curves of WT (n = 35), KO (n = 35), and KO+celecoxib (n = 20) groups. C, Histogram of average lifetimes of KO (16.0 ± 1.7 d, n = 35) and KO+celecoxib (21.1 ± 2.2 d, n = 20) mice. D, EEG recordings from WT, LGI1+/−, and celecoxib-treated LGI1+/− mice (P35) when PTZ was injected intraperitoneally. E, Averaged seizure scores in mice. WT, 1.5 ± 0.7 (n = 15); LGI1+/−, 3.0 ± 0.7 (n = 15); LGI1+/−+celecoxib, 1.3 ± 0.4 (n = 15). F, Quantification of reactions to PTZ injection. ***p < 0.001.